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Abstract
Gallbladder cancer represents one of the rare and highly fatal neoplastic diseases, early diag-
nosis and treatment being the key for an acceptable outcome. The best survival results are 
obtained for patients with T1-T2 stage, a radical cholecystectomy being sufficient in most 
of these cases. For advanced tumors, major liver resections could be necessary to obtain 
optimal oncological results. Although a high percentage of the patients are diagnosed with 
unresectable disease, the continuous progresses made in the field of surgical therapy and 
oncological treatment could finally improve the outcome of this neoplastic pathology.
Keywords: gallbladder cancer, surgical treatment, hepatic resection, radical 
colecistectomy, hepatic limphadenectomy
1. Introduction
Biliary tract cancers are a group of neoplastic diseases that arise from the biliary epithelium. 
According to their localization, they are divided into: intrahepatic cholangiocarcinoma, peri-
hilar cholangiocarcinoma, distal cholangiocarcinoma and gallbladder cancer. Gallbladder 
cancer represents one of the rare and highly fatal neoplastic diseases; early diagnosis and 
treatment are the key [1].
2. Epidemiology: risk factors
Gallbladder cancer is the fifth most common type of digestive cancer and the most frequent 
biliary tract cancer. The maximum incidence of this disease is reported in Chile, Bolivia and 
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other South-American countries [2]. Urban population presents a higher risk of developing 
gallbladder cancer [1]. The prognosis is a very poor one, with a 5-year overall survival rate 
of less than 10% [2]. During the last decade, the mortality rate has improved in developed 
countries, while in developing countries it is still at a high level [1]. Chronic inflammation of 
the gallbladder mucosa and all its predisposing factors increase the incidence of the disease. 
The most common risk factors for developing gallbladder cancer are: gallbladder lithiasis, old 
age, female sex, tobacco and alcohol abuse, multiple pregnancies, low physical activity, obe-
sity and infectious diseases. The most common pathogens implicated in the development of 
gallbladder cancer are Salmonella typhi, Salmonella paratyphi and Helicobacter [1]. Gallstones, 
especially large ones, frequently associated with Mirizzi syndrome, represent the most com-
mon predisposing factor for gallbladder cancer [1]. Gallbladder polyps, the porcelain gall-
bladder and anatomical abnormalities of the ampulla of Vater, which causes bile reflux, are 
also predisposing factors. Diet is another important risk factor in the development of gall-
bladder cancer; increased intake of fried foods or those that cause constipation (less than 
one bowel movement in 6 days) increases the risk. On the other hand, in women, the intake 
of boiled beans, or in men, the intake of fish, lowers the incidence of gallbladder cancer. The 
involvement of environmental factors such as heavy metals (high levels of nickel, cadmium, 
manganese, copper, chromium and lead, as well as low levels of selenium or zinc) is not yet 
fully understood, requiring prospective studies conducted on large groups of patients [1]. 
Also, mutations of K-ras or p53 genes are still being studied; identifying a link between these 
mutations and the development of gallbladder cancer is still difficult [1].
A separate entity is represented by incidental gallbladder cancer discovered at histopatho-
logical examination of specimens resulted from cholecystectomy performed for gallbladder 
lithiasis [3]. These cases represent 47% of all cases of gallbladder cancer [4].
3. Pathology
Gallbladder cancer develops similar to other digestive cancers: the progression can be 
observed from dysplasia to infiltrative carcinoma at the level of gallbladder mucosa. The pre-
neoplastic nature of gallbladder polyps is controversial, however there is some data showing 
the progression to adenocarcinoma. About 3–6% of the patients present with gallbladder pol-
yps at the ultrasound examination [5]. Most of them are cholesterol polyps without any risk 
of becoming malignant. The risk of polyps for becoming malignant has been associated with 
old age, dimensions over 1 cm and the presence of a single polyp [5].
Gallbladder cancer presents most often as monocentric; multifocal forms are extremely rare. 
The most common localization is at the fundus of the gallbladder (60%), followed by the body 
(30%) and the infundibulum (10%) [5].
These tumors are considered highly aggressive since infiltrative forms are rapidly involving 
hepatic parenchyma, mostly segments IVb and V. Also, tumor extension can occur towards 
the cystic duct and its confluence with the common hepatic duct, in which case the presenta-
tion could be similar to a Klatskin tumor [6]. Malignant tumors of the gallbladder can invade 
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the branches of the hepatic artery or portal vein, which leads to the atrophy of the ipsilateral 
lobe and compensatory hypertrophy of the contralateral lobe.
The most common histological type of gallbladder malignant tumor is adenocarcinoma. The 
papillary form of adenocarcinoma has the best prognosis because this type of tumor tends to 
be noninvasive or minimally invasive [5]. However, we must not forget the other histological 
types, such as squamous cell or adenosquamous carcinoma, mucinous carcinoma, signet ring 
cell carcinoma and not least lymphomas and neuroendocrine tumors. Rare forms are repre-
sented by melanomas or secondary tumors localized at the level of the gallbladder.
Gallbladder cancer most commonly spreads directly into the surrounding organs. Step by 
step spreading is further enabled by thin gallbladder wall, which is formed by only one mus-
cular layer and by the fact that the connective tissue of the gallbladder is continuous with 
the interlobular connective tissue of the liver [7]. This highly aggressive malignant tumor 
also spreads through satellite lymphatic vessels of the cystic duct to the hilar lymph nodes 
and further to the gastroduodenal lymph nodes, retropancreatic lymph nodes, celiac trunk 
lymph nodes and finally to the interaortocaval lymph nodes. Advanced cases of the disease 
determine enlarged lymph nodes at the level of the hepatic hilum, which erode and invade 
the portal vein wall, causing thrombosis and all the consequences of portal hypertension. 
Spreading to the peritoneum, which determines the occurrence of paraneoplastic ascites, as 
well as pulmonary and hepatic metastases, determine the infaust evolution of terminal cases.
4. Diagnosis
Gallbladder cancer can be diagnosed either preoperative or intraoperative during surgical 
treatment for another disease or after the histopathological examination of the specimen 
resulted from cholecystectomy for gallbladder lithiasis. The clinical signs of gallbladder can-
cer are not specific, which is why more than half of the cases cannot be diagnosed preopera-
tively. The lack of efficient screening methods for this disease also leads to the impossibility 
of an early diagnosis. The systematic examination of the specimens resulting from cholecys-
tectomy improved the early diagnosis rate of this extremely aggressive neoplastic disease.
Even though clinical signs and symptoms are not specific, knowing and following them in 
patients suspected of having this disease is particularly important for proper management. 
Symptoms associated with gallbladder lithiasis or choledochal lithiasis are commonly found 
in the clinical presentation of gallbladder cancer. So, in symptomatic patients, abdominal pain 
with the character of biliary colic is a common sign, especially in cases when the cancer is 
diagnosed incidentally, during the treatment for an acute or chronic cholecystitis.
Jaundice and angiocholitis are also frequently seen in the clinical presentation of the gallblad-
der cancer [6]. In addition to jaundice, we can observe other paraneoplastic signs and symp-
toms like asthenia, fatigue and marked weight loss.
The physical examination of the patients reveals discomfort in the right hypochondrium, 
where it can also be found as a hard mass, which is poorly delimited and fixed due to tumor 
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invasion of surrounding organs. If gallbladder cancer is suspected, some laboratory tests and 
imaging examinations must be performed in order to establish a correct diagnosis.
Required laboratory tests are the usual ones and they determine mainly an extrahepatic cho-
lestasis syndrome. Prolonged biliary stasis can also determine high levels of serum transami-
nases and other parameters that show liver failure. Most of the times, the laboratory findings do 
not establish an accurate diagnosis unless they reveal an advanced stage of disease. Biological 
signs of advanced disease are: anemia, low levels of serum albumin, high levels of leukocytes 
and extremely high alkaline phosphatase and conjugated bilirubin levels [5]. Relevant tumor 
markers are CEA and CA 19-9. A high level of CEA has a specificity of 90% for malignant 
tumors of the gallbladder, but has a low sensitivity (50%) [5] when it is used for screening 
because it is also elevated by benign tumors. The tumors markers have a low utility for gall-
bladder cancer’s diagnosis but they are extremely important for the follow-up of these patients.
Imaging exams are crucial for diagnosing and staging of this disease and they usually reveal 
asymmetric thickness of the gallbladder wall. Since polyps or malignant tumors of the gall-
bladder could have similar imaging characteristics to the normal gallbladder wall, an accurate 
diagnosis is difficult to establish. The situation can be further complicated by a certain degree 
of inflammation of the gallbladder wall caused by lithiasis.
The ability of ultrasound examination to reveal this disease has been appreciably improved 
by employing ecoendoscopic techniques, which in some cases is even more accurate than 
computed tomography (CT) or magnetic resonance imaging (MRI) [6]. CT imaging with intra-
venously administered contrast may reveal a tumor at the level of the gallbladder, which 
invades hepatic parenchyma and other adjacent organs. Despite this, an accurate staging 
using CT is hard to achieve due to the weak sensitivity for identifying possible lymph node 
metastases [6]. MRI has better sensitivity for both identifying possible lymph node metastases 
and for revealing any invasion at the level of the adjacent hepatic parenchyma. This is best 
evidenced by MRI T2 sections [8].
5. Staging
Staging is a key moment in the management of patients presenting with malignant gallblad-
der tumors. The American Joint Committee on Cancer (AJCC) proposes the tumor-lymh 
nodes-metastasis (TNM) staging as follows (Table 1).
Complete staging is obtained by a combination of imaging: ultrasound, CT, MRI, positron 
emission tomography (FDG-PET) and diagnostic laparoscopy. Diagnostic laparoscopy is 
superior in identifying possible peritoneal spread, as well as other absolute contraindications 
for radical surgery. Its employment has lead to a decreased rate of blind laparotomies [9].
Diagnostic laparoscopy combined with intraoperative ultrasound techniques, with or with-
out contrast, has better sensitivity in identifying liver metastases and allows for a more pre-
cise evaluation of tumor adjacent blood vessels involvement. The invasion of adjacent organs 
(liver, stomach, duodenum, pancreas, colon, greater omentum and abdominal wall) can also 
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been revealed through laparoscopy. In case of a suspected distant metastasis, the FDG-PET 
examination is recommended [6].
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor invades lamina propria or muscular layer
T1a Tumor invades lamina propria
T1b Tumor invades muscular layer
T2 Tumor invades perimuscular connective tissue; no extension beyond serosa or into 
liver
T3 Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver 
and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, 
pancreas, omentum, or extrahepatic bile ducts
T4 Tumor invades main portal vein or hepatic artery or invades two or more extrahepatic 
organs or structures
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastases to nodes along the cystic duct, common bile duct, hepatic artery and/or 
portal vein
N2 Metastases to periaortic, pericaval, superior mesenteric artery and/or celiac artery 
lymph nodes
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Anatomic stage/prognostic groups
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage IIIA T3 N0 M0
Stage IIIB T1–3 N1 M0
Stage IVA T4 N0-1 M0
Stage IVB Any T N2 M0
Any T Any N M1
Table 1. TNM staging (after AJCC 7th edition).
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The preoperative histopathological diagnosis is not considered necessary in case of clinical or 
imagistic suspicion of gallbladder cancer, because during biopsy, peritoneal or biopsy tract 
spreading may occur. In addition, the rate of false negative results of biopsies is significant [5]. 
As such, a negative biopsy must not be taken into consideration.
6. Surgical treatment of gallbladder cancer
The treatment of gallbladder cancer is a multimodal one and implicates a multidisciplinary 
team. Needless to say, the treatment methods must be adapted both to the patient’s status and 
the stage of the disease [3]. Surgical treatment remains the only curative alternative, but its 
results have been improved by the emergence of new oncologic treatments. Surgical treatment 
is done according to the stage of the disease and is divided in two categories: curative and pal-
liative. It is necessary to identify the absolute contraindications for radical surgery. These are: 
liver metastases, peritoneal carcinomatosis, involvement of N2 lymph nodes (lymph nodes of 
the celiac trunk, peripancreatic lymph nodes, periduodenal lymph nodes and superior mes-
enteric lymph nodes) and the invasion to the lesser omentum or of greater blood vessels [9]. 
If at least one of the contraindications above is identified, surgery can be considered just for 
palliation. The invasion of adjacent organs (colon, duodenum and liver) does not represent 
an absolute contraindication to radical surgery; en bloc resection of the tumor and invaded 
organs could be performed [3].
6.1. Radical treatment: indications and prognosis
6.1.1. T1 tumors
Usually, incidentally diagnosed cancers on specimens resulting from cholecystectomy are 
T1a tumors. These lesions are limited to the lamina propria and the performed cholecystec-
tomy is considered to be sufficient if obtained resection margins are negative. In cases with 
T1b tumors, due to the 50% 1-year survival rate [3], a follow-up on the initial intervention 
with a resection of IVb and V segments of the liver (Figure 1) and limphadenectomy along 
the portal pedicle is necessary.
6.1.2. T2 tumors
For this type of tumors, simple cholecystectomy is not sufficient. Hepatic resection and loco-
regional lymphadenectomy is necessary. Major hepatic resections (right hepatectomy or 
extended right hepatectomy) may be necessary if the invasion of the right branch of the portal 
vein occurs. Simple cholecystectomy performed in T2 tumors offers a 5-year survival rate of 
40%, compared to an 80% 5-year survival rate for en bloc resections of the tumor [3]. Given 
its close anatomical relation with the gallbladder, the right branch of the portal pedicle is 
most susceptible to tumoral invasion. In some cases, in order to obtain negative resection 
margins, it is necessary to perform a bile duct resection and a biliodigestive anatomosis. 
Thus, an extemporaneous examination of the cystic stump is vital for certifying oncologic 
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radicality. It is important that bile duct resection to be performed in attentively selected cases 
where the benefit outweighs the complication rate of the necessary biliodigestive anastomo-
sis [1]. Lymphadenectomy is demonstrated to improve the prognosis if N1 lymph nodes are 
involved, whereas in patients presenting N2 lymph nodes involvement, lymphadenectomy 
will not bring certain benefits [3]. Thus, N2 lymph nodes involvement represents a negative 
factor in patient outcome.
6.1.3. T3 tumors
As in the case of T2 tumors, for T3 tumors, simple cholecystectomy is not considered sufficient 
from an oncological point of view. Hepatic resection and loco-regional lymphadenectomy are 
necessary. If adjacent organs are involved, en bloc resection is necessary due to the difficulty 
in distinguishing, from a macroscopic point of view, between inflamed tissue and tumor inva-
sion. A 5-year survival rate between 30 and 50% is obtained in case of R0 resections [3].
6.1.4. T4 tumors
T4 classified tumors are in most cases unresectable without any oncologic radicality preten-
tion. In this stage, the palliative surgical approach combined with chemoradiotherapy is the 
only therapeutic alternative [3].
Figure 1. Resection of segment IVb-V, “in block” with the tumoral gallbladder. Dissection of the glissonian pedicles 
(intraoperative aspect, from the personal archive of the authors).
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6.2. Surgical technique
6.2.1. Open and laparoscopic cholecystectomy
Simple cholecystectomy is the surgical intervention whereby the gallbladder and a portion of 
the cystic duct are removed. This can be performed either open or by laparoscopy. Regardless 
of the approach, three types of cholecystectomy can be distinguished: retrograde, anterograde 
or bipolar. In cases presenting with T1a gallbladder tumors, simple cholecystectomy is suf-
ficient for obtaining a radical resection. Most guidelines state that in surgical oncology, the 
preferred approach is the open one, but due to a substantial improvement in laparoscopic 
techniques, the latter have gained popularity in recent years.
Cholecystectomy is usually performed with the patient placed in a supine position with the 
arms abducted, the main surgeon being situated on the patient’s right side. The laparotomy 
is usually done through a right subcostal incision. For the laparoscopic approach, multiple 
variants of trocar placement have been described; it is the surgeon’s decision to choose the 
preferred method. After entering the peritoneal cavity, the first surgical step is to evaluate the 
local situation and to perform adhesion’s dissection, for a better view of the region of inter-
est. At the same time, the peritoneal cavity is inspected for evidence of possible associated 
pathologies such as peritoneal carcinomatosis or paraneoplastic ascites and to evaluate the 
subhepatic region.
The cholecystectomy can be performed either retrograde (with the primary dissection of the 
gallbladder pedicle at the level of Calot triangle) or anterograde (with primary dissection of 
the gallbladder from its hepatic fossa). The anterograde cholecystectomy may be useful in 
cases where the primary dissection of Calot triangle is difficult due to adhesions or anatomic 
modifications.
The most important moment in performing the cholecystectomy is the dissection of Calot 
triangle, where the elements of the gallbladder pedicle are located. The isolation, ligation and 
resection of the cystic duct and artery are performed at this level. At this point in the proce-
dure, the prelevation of a sample from the cystic duct stump is necessary for performing the 
histopathological assessment of the resection margin. The next step of the procedure is the 
dissection of the gallbladder from its hepatic fossa using the electrocautery. Following that, 
the gallbladder extraction is performed through the subxiphoidian incision, with or without 
the enlargement of the aponeurosis. Given the high risk of spreading malignant cells into the 
abdominal wall, the gallbladder is extracted using an endobag.
There is at least a theoretical risk of trocar port or peritoneal tumoral recurrence. The risk of 
peritoneal tumor spreading is increased by the leakage of bile or calculi from the gallblad-
der during its dissection. For this reason, the dissection of the gallbladder from its hepatic 
fossa needs to be performed with increased attention in order to minimize the risk of creating 
breaches into the gallbladder wall. Port-site excision is to be considered in case when the diag-
nosis is made incidentally based on the histopathological assessment of the cholecystectomy 
specimen. The practice of excising port-sites is not routinely imposed as it does not modify the 
survival rate of these patients [10].
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6.2.2. Radical cholecystectomy
In cases with gallbladder tumors staged over T1a, the required surgical approach is 
radical cholecystectomy, combined, in selected cases, with liver resections. Radical cho-
lecystectomy is defined as the removal of the gallbladder and the hepatic parenchyma 
corresponding to its fossa, with a resection margin of minimum 2 cm [11]. After exposing 
the subhepatic region, the liver parenchyma corresponding to gallbladder fossa is marked 
using the electrocautery. The blood loss from transected liver parenchyma can be mini-
mized by using recent generation surgical instruments, as well as intra-anesthetic lower-
ing the central venous pressure. The Calot triangle dissection is performed in the same 
manner as for simple cholecystectomy. The specimen obtained is sent for extemporane-
ous histopathological assessment of the resection margins. If the margins are negative, a 
portal pedicle lymphadenectomy is performed. If the resection margins are positive, the 
resection must be completed by either resecting more liver parenchyma or by the resection 
of the bile duct with performing a bilio-digestive anastomosis. If it is necessary to resect 
more liver parenchyma, an anatomical resection of segments IVb and V is considered to 
be appropriate [5].
6.2.3. Resection of segments IVb and V
After entering the abdominal cavity through a right subcostal incision, the liver and the sub-
hepatic region are assessed. After splitting the hepatic parenchyma to the right side of the 
falciform ligament, the inflow vessels to segments IVa and IVb are identified and only the 
vessels to segment IVb are ligated and divided, preserving segment IVa. After this, the tran-
section of the liver parenchyma is performed and the middle hepatic vein is identified and 
divided in the middle of the liver. As the transection continues, the pedicle of segment V is 
identified, ligated and divided. A lot of attention should be given not to damage the right 
and left hilar structures during transection. After the specimen is removed, the hemostasis 
control is performed and the abdominal cavity is drained. The abdominal wall is closed in 
anatomical layers [5, 12].
6.2.4. Extended liver resections
Extended liver resections are necessary especially if the tumor is localized at the level of body 
or infundibulum of the gallbladder. Most frequently, it is necessary to perform an extended 
right hepatectomy, due to the close anatomic relation between the gallbladder and the right 
portal pedicle. In numerous cases, it is difficult to distinguish between inflamed tissue and 
tumoral invasion at the level of the right portal pedicle and it is necessary to perform the right 
hepatectomy to ensure a curative surgical attempt.
The right hepatectomy is defined as the removal of segments V, VI, VII and VIII of the liver. 
The extended right hepatectomy imply additional resection of segment IV. After entering 
the peritoneal cavity through a right subcostal incision (Kocher incision), the first surgical 
step is to mobilize the liver by cutting the falciform, right triangular and coronary ligament. 
After the liver is mobilized, a visual and manual assessment of the liver is mandatory. By 
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incising the hepato-duodenal ligament, the portal pedicle is visualized. It is crucial not to 
injure the left portal pedicle during dissection. By dissecting towards Calot triangle, the cys-
tic artery and duct are isolated, ligated and divided. After the dissection at the level of the 
portal pedicle is made, the right branch of the hepatic artery and the right portal branch are 
isolated, ligated and divided to obtain a control on the blood inflow. The right hepatic duct 
may be ligated and sectioned by the time when liver transection is performed. Next step to 
be performed is the exposure of the right hepatic vein. By turning the liver to the left, a good 
assessment of the hepatic veins can be made, at the caval confluence. There might be some 
collateral veins that drain directly into the inferior vena cava and they must be carefully 
identified, ligated and divided. After the right hepatic vein is isolated, ligated and divided, 
the next step is the liver transection. This surgical step can be performed in multiple ways, 
with or without the use of recent generation surgical instruments. A fast way to perform liver 
transection is by using a Kelly clamp to crush the liver tissue and identify, ligate and divide 
the vasculo-biliary structures. After the transection is made, the diffuse blood loss from the 
liver tissue can be controlled with surgical devices such as plasma scalpel. For adjunctive 
hemostasis, a fibrin sealant patch may be used. After removing the right liver, an assessment 
of the whole surgical field is mandatory to identify any source of bleeding or bile leakage. 
Finally, drainage of the abdominal cavity is recommended. The abdominal wall is closed in 
anatomical layers [13].
6.2.5. Bile duct resection
Extrahepatic bile duct resection is necessary either if a tumoral invasion of the common 
bile duct is present or if at the extemporaneous histological assessment, malignant cells are 
revealed at the level of the cystic duct stump. Once negative margins are obtained, the conti-
nuity of the biliary tract is restored through a Roux-en-Y hepaticojejunostomy [11].
6.2.6. Lymphadenectomy
The status of the lymph nodes represents an important prognosis factor for all patients 
undergoing surgery for gallbladder cancer. Lymphadenectomy is mandatory in all cases of 
tumors staged T1b and above, even if there are no macroscopic signs of lymphatic spread. 
The prognosis in significantly improved in patients for which the lymphadenectomy is per-
formed; the 5-year survival rate increases to 57%, compared to only 12% in cases where the 
lymphadenectomy was not performed [14]. The D1 lymphadenectomy is defined by the 
removal of lymph nodes situated at the level of the hepatic pedicle and the hepatico-duo-
denal ligament (cystic artery, hepatic artery, portal vein and common bile duct) (Figure 2). 
The extended lymphadenectomy (D2) consists of extending the lymphadenectomy to the 
N2 classified lymph nodes: periaortic, celiac artery, superior mesenteric artery and infe-
rior vena cava nodes. This type of lymphadenectomy should be performed in cases where 
this is possible without performing large scale surgical procedures, which increase the risk 
of postoperative complications. The only certain benefit of performing the D2 lymphad-
enectomy is obtaining a more accurate staging; the patient survival rate is not significantly 
influenced [14, 15].
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6.3. Palliative treatment
When unresectable gallbladder cancer is certain, it is important to aid the patient by apply-
ing a palliative treatment that is meant to improve the quality of life. Patients in an advanced 
stage of the disease are often presenting with jaundice, pruritus, pain in the upper right 
abdominal quadrant or bowel obstruction [12]. The optimal palliative procedure is one that 
provides the remission of symptoms with a minimum of risk (Table 2) [12]. The palliation can 
be performed either endoscopically or surgically, the approach depending on the biological 
status of the patient and the prognosis of the disease. Surgical jaundice palliation presents a 
higher rate of complications compared to the endoscopic approach [16].
6.3.1. Bilio-digestive anastomosis
Performing a bilio-digestive anastomosis is necessary for unresectable locally advanced 
tumors, which cause jaundice. In most cases, a locally advanced tumor invades the conflu-
ence of the hepatic ducts, so a Roux-en-Y hepaticojejunostomy is not viable [12]. In these 
situations, endoscopic drainage by transtumoral stenting or ultrasound/CT-guided external 
transparietohepatic biliary drainage can be the only alternative.
6.3.2. Digestive bypass
Digestive bypasses represent a method of palliation used for patients presenting with bowel 
obstruction caused by tumoral invasion of the duodenum or colon. If the duodenum is 
Figure 2. Lymphadenectomy along the portal pedicle. PHA, proper hepatic artery, RHA, right hepatic artery, LHA, left 
hepatic artery, CBD, common bile duct, PV, portal vein (intraoperative aspect, from the personal archive of the authors).
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involved, an Omega or Roux-en-Y gastroenteroanastomosis should be performed. If the colon 
is involved (a rare occurrence), an internal bypass is the most frequently used method.
7. Oncological treatment
Oncological treatment supports the surgical act and is meant to improve the outcome of gall-
bladder cancer patients. The prognosis of this pathology is extremely poor, with a high rate of 
recurrence, even in patients undergoing radical surgical treatment. Thus, efficient oncological 
treatment is necessary in order to improve the rate of survival. There are few randomized 
trials conducted on patients with resectable tumors, so the efficacy of adjuvant oncological 
therapy cannot be well assessed. At the same time, oncological treatments can be used for pal-
liative purposes in patients presenting unresectable tumors. The following paragraphs sum-
marize the different types of oncological treatment.
7.1. Adjuvant treatment
Due to a high rate of recurrence, adjuvant treatment comes in the form of radiotherapy, pos-
sibly combined with chemotherapy [17]. A meta-analysis of 20 studies (6712 patients) evaluat-
ing the impact of chemotherapy, radiotherapy and their combination performed for adjuvant 
purposes, indicates an insignificant benefit in unselected cases. However, in cases of sub-
groups of patients defined as presenting an increased risk of recurrence (positive resection 
margins or an advanced degree of lymph node involvent), adjuvant therapy provides a posi-
tive influence on prognosis [17].
A consensus regarding the optimal adjuvant therapy has not been reached; there are multiple 
methods of applying this type of treatment. Due to the high risk of distant metastasis occur-
rence, a possible avenue of treatment can be starting with 6 months of chemotherapy, which can 
lead to avoiding unnecessary radiotherapy for patients that develop distant metastases (cases 
that would not benefit from radiotherapy anyway) [18]. In the case of patients who have positive 
Symptom Palliative method
Jaundice Endoscopic placement of a stent
Pruritus Surgical bilio-digestive anastomosis
Pain Celiac trunk alcoolization
• Percutaneous
• Ecoendoscopic
• Laparoscopic
Bowel obstruction Gastroenteroanastomosis (invasion of the duodenum)
Digestive bypass (invasion of the colon)
Table 2. Palliative options for unresectable gallbladder cancer.
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resection margins, combined treatment (chemotherapy and radiotherapy) is recommended. An 
option is to perform intraoperative radiotherapy. This is meant to improve the prognosis but 
there is little evidence indicating a real benefit of this treatment [19]. One advantage of intraop-
erative radiotherapy is the possibility of targeted administration of a high dosage of radiation 
directly on the tumor, while protecting the adjacent, highly radiosensitive, tissues [18].
7.2. Palliative oncological treatment
In cases of unresectable tumors (see Section 6) palliative chemoradiotherapy can be per-
formed. In the past, the used chemotherapic treatment was 5-FU, Methotrexate, Mitomicin C 
and Doxorubicin, with a response rate of 10–20% [5]. More recently, the use of gemcitabine 
and oxaliplatin has improved the response rate up to 50%. On the other hand, radiotherapy 
has a palliative effect for locally advanced tumors (stages T3 and above) and is usually well 
tolerated and insures the remission of symptoms [5]. Radiotherapy is most commonly used in 
combination with chemotherapy.
8. Outcomes
8.1. Perioperative morbidity and mortality for radical interventions
The perioperative risk depends on the stage of the disease and the biological status of the patient. 
It is important to balance the risk of surgery to the risk of the untreated disease. Surgery should 
be performed with curable intent just when the patient is capable to support it. If the biological 
status of the patient does not support a radical approach it should be ameliorated preoperatively.
Gallbladder cancer surgery is accompanied by a lot of possible complications, some of them 
very difficult to manage. Most feared complications are: postoperative bleeding, bile leak and 
perihepatic abscess.
The perioperative mortality rate is significantly higher in patients with extended hepatic 
resections compared with those who underwent limited resections (resection of segments 
IVb and V), radical cholecystectomy or simple cholecystectomy [20]. An improvement in the 
outcome of patients underwent extended liver resection has been obtained by the progresses 
made in the field of surgical techniques, anesthetic and intensive care management.
Long-term outcome is extremely poor due to the high aggressive nature of this type of can-
cer. Only patients staged T1 have better long-term outcome, but unfortunately only approxi-
mately 10% of symptomatic patients reveals to be T1 and up to 20% from the incidentally 
diagnosed patients have T1 tumors.
8.2. Survival rate after radical treatment
The survival rate of patients undergoing surgery for gallbladder cancer depends of the dis-
ease’s stage.
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For T1a tumors, limited to the lamina propria, radical resection is obtained by simple cho-
lecystectomy in many cases. The 5-year overall survival rate of these patients is reported to 
range between 97 and 99% [21].
For T1b and T2 patients, the oncologic radicality is easy to obtain by performing a liver resec-
tion including segments IVb and V, combined with lymphadenectomy at the level of the 
lesser omentum. The 5-year survival rate in these cases, if the appropriate surgical approach 
is performed, ranges between 59 and 90% [21].
For T3 and T4 tumors, it becomes challenging to balance the surgical risk of an extensive 
resection with the possible benefit. It is known that if a more extensive liver resection is per-
formed, a higher rate of complications may occur. However, by recent improving of the sur-
gical techniques, the rate of complications after major liver surgery has been improved and 
more extensive resections can be made with a diminished morbidity and mortality rate. The 
5-year survival rate is reported to be 25% after major resections.
8.3. Survival rate for palliative treatment
Patients presenting unresectable gallbladder tumors benefit from palliative treatment to increase 
their quality of life. The overall survival rate is not significantly improved by palliative treat-
ment, but there may be some benefits of chemoradiotherapy (as we discussed in Section 7.2).
8.4. Survival rate without treatment
Advanced gallbladder cancer has a very poor survival rate without any treatment even if the 
patient has a good performance status. The overall survival is 4.4 months for unresectable and 
untreated gallbladder cancers [20]. The presence of metastases at the moment of the diagnosis 
appeared to decrease the survival rate.
9. Future perspective
9.1. Intraoperative ultrasonography
Because preoperative imagistic staging of gallbladder cancer is difficult, the intraoperative 
ultrasound techniques are more and more used to obtain an accurate staging before choos-
ing an appropriate surgical approach. The staging laparoscopy can be combined with the 
ultrasonographic assessment of the tumor to improve the accuracy of the diagnosis. As it is 
shown by a recent meta-analysis, the sensitivity of staging laparoscopy is improved when 
it is associated with intraoperative ultrasonography from 55.9 to 65.7% [22]. Laparoscopic 
ultrasonography is used for identification of liver lesions and for showing the precise location 
of the tumor and its relations with surrounding blood vessels. However, the intraoperative 
ultrasound assessment of hepatic hilum is very difficult and requires an experienced surgeon 
with high knowledge of liver imaging. The sensitivity of intraoperative ultrasound has been 
improved by the use of micro-bubble agents [23].
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9.2. Navigation surgery
This new concept is being used in other surgical specialties, but in visceral surgery its usage 
is just at the beginning. Intraoperative navigation is a new technique that, with the use preop-
erative tomographic images, provides a virtual imaging of the anatomical region of interest so 
both the patient safety and the accuracy of the surgical procedure are improved [24].
9.3. Intraoperative fluorescence
Indocyanine is a fluorescent agent that has been used to evaluate the liver function. More 
recently, indocyanine is used for assessing the involvement of lymph nodes during breast 
and digestive surgery. In surgery of the liver, indocyanine has also been used for detecting 
the exact location of the tumors, the liver segmentation and biliary leakage. The role of this 
method is not completely understood. A disadvantage of the method is represented by the 
fact that only superficial tumors can be detected, due to limited depth of detected tissue [23]. 
There are few studies that assess the role of intraoperative fluorescence with indocyanine and 
further studies should be conducted to have a better view on this innovative technique.
10. Key points
• Extremely difficult early diagnosis and poor long-term outcome makes the gallbladder 
cancer an issue in the field of cancer management.
• Early diagnosis (T1a–b) is crucial; only a radical treatment will provide a proper long-
term survival rate.
• The tumors that are staged T2 or T3 have an extremely poor prognosis, even if extended 
lymphadenectomies and hepatic resections are performed.
• Depending on the cancer spreading and the complications that follow, palliative onco-
logic treatment can be combined with certain surgical approach in cases with T4-staged 
tumors.
• The role of adjuvant and neoadjuvant therapies is not yet clearly established; the long-
term outcome is not significantly improved by these.
• The continuous development of screening and diagnostic methods, combined with the 
improvement of surgical techniques due to intraoperative imaging, may lead to better 
outcome for the patients treated with gallbladder cancer.
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